News|Articles|February 21, 2025

Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU

Fact checked by: Tim Cortese

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

The 2025 ASCO Genitourinary Cancers Symposium exhibited several updates in the management of various genitourinary cancers, with late-breaking abstract presentations and poster sessions alike highlighting potential advancements in the treatment of patients with bladder cancer, prostate cancer, kidney cancer, and other malignancies. These findings elucidated how modalities such as tyrosine kinase inhibitors and antiandrogen agents may continue to impact the treatment paradigm.

Related to this article

“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.

October 9th, 2026

Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer

“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.

Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.

October 9th, 2026

Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization

Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.

$Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.$

October 9th, 2026

Ramantamig Achieves “Impressive” Rates of MRD Negativity in RRMM

Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.

In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.

October 9th, 2026

Selcodebart Yields Hematologic Responses in Anemia From Myelofibrosis

In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.

Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.

October 8th, 2026

How to Navigate Ramantamig’s Low-Grade Toxicities in Multiple Myeloma

Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.

“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.

October 8th, 2026

How Can Cooperative Groups Close Outcome Gaps in HIV-Associated Lymphoma?

“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.

October 7th, 2026

Weighing Safety vs Persistence With CAR NK Cell Therapy

Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.

“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.

October 7th, 2026

What Does NRG GU002 Mean for Docetaxel After Prostatectomy?

“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.